Lupus Clinical Trials in New York

41 recruiting studies across 1 city

Browse by City

All Trials in New York

Phase

Trial	Phase	Sponsor	Dist.
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis	Phase 3	Novartis Pharmaceuticals	<1 mi
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease	Phase 1	Allogene Therapeutics	<1 mi
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer	Phase 1	National Cancer Institute (NCI)	<1 mi
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus	Phase 3	UCB Biopharma SRL	<1 mi
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus	Phase 2/3	Biogen	<1 mi
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus	Phase 3	AbbVie	<1 mi
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus	Phase 3	AstraZeneca	<1 mi
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis	Phase 3	AstraZeneca	<1 mi
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants	Phase 3	AstraZeneca	<1 mi
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)	Phase 1/2	Nkarta, Inc.	<1 mi
Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)	—	The Rogosin Institute	<1 mi
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)	—	Hospital for Special Surgery, New York	<1 mi
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine	Phase 2	State University of New York - Upstate Medical University	<1 mi
VIBRANT: VIB4920 for Active Lupus Nephritis	Phase 2	National Institute of Allergy and Infectious Diseases (NIAID)	<1 mi
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)	Phase 2	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	<1 mi
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus	Phase 1	Columbia University	<1 mi
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus	Phase 1	Bristol-Myers Squibb	<1 mi
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study	Phase 2	Children's Hospital Medical Center, Cincinnati	<1 mi
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)	Phase 1	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	<1 mi
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus	Phase 1/2	Cabaletta Bio	<1 mi
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease	Phase 3	NYU Langone Health	<1 mi
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)	—	Ampel BioSolutions, LLC	<1 mi
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE	Phase 1/2	AstraZeneca	<1 mi
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases	Phase 2	Amgen	<1 mi
Safety of the Herpes Zoster Subunit Vaccine in Lupus	Phase 4	NYU Langone Health	<1 mi
Alnuctamab for Refractory SLE (LATTE Study)	Phase 1	Icahn School of Medicine at Mount Sinai	<1 mi
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy	Phase 2	David Ware Branch	<1 mi
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus	Phase 1	Cullinan Therapeutics Inc.	<1 mi
Safety and Efficacy of ONT01 in Lupus	Early 1	Hospital for Special Surgery, New York	<1 mi
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132	Phase 4	Bristol-Myers Squibb	<1 mi
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease	Phase 1	Fate Therapeutics	<1 mi
Lupus Landmark Study: A Prospective Registry and Biorepository	—	Lupus Research Alliance	<1 mi
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus	Phase 2	Sanofi	<1 mi
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants	—	Bristol-Myers Squibb	5 mi
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)	Phase 4	GlaxoSmithKline	5 mi
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants	Phase 2	Hoffmann-La Roche	9 mi
Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus	N/A	Michigan State University	12 mi
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus	Phase 3	Viatris Innovation GmbH	12 mi
Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus	—	Northwell Health	17 mi
Trial of Belimumab in Early Lupus	Phase 4	Northwell Health	17 mi
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V	Phase 2	Novartis Pharmaceuticals	50 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.